Improving Vaccine Performance with Adjuvants
Open Access
- 1 June 2000
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 30 (Supplement) , S266-S270
- https://doi.org/10.1086/313883
Abstract
New vaccines are presently under development and in testing for the control of infectious diseases, including human immunodeficiency virus (HIV) andKeywords
This publication has 67 references indexed in Scilit:
- Increasing the immunogenicity of a trivalent influenza virus vaccine with adjuvant-active nonionic block copolymers for potential use in the elderlyMechanisms of Ageing and Development, 1997
- Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59Vaccine, 1995
- Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutideInternational Journal of Immunopharmacology, 1995
- Accessory Cell Requirements for Saponin Adjuvant-Induced Class I MHC Antigen-Restricted Cytotoxic T-LymphocytesCellular Immunology, 1994
- Comparison of Adjuvant Activities of Aluminium Phosphate, Calcium Phosphate and Stearyl Tyrosine for Tetanus ToxoidBiologicals, 1994
- Efficacy of inactivated whole HIV‐2 vaccines with various adjuvants in cynomolgus monkeysJournal of Medical Primatology, 1994
- Adjuvants: current status, clinical perspectives and future prospectsImmunology Today, 1993
- Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: The role of endogenous interleukin 1 in proliferative responsesCellular Immunology, 1989
- Structure and Function of Human and Murine Receptors for IgGAnnual Review of Immunology, 1988
- Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivativesBiochemical and Biophysical Research Communications, 1974